Friday 21 Mar 2025
By
main news image

KUALA LUMPUR (Feb 12): Yenher Holdings Bhd (KL:YENHER) is now better positioned to weather African swine fever (ASF) risks thanks to its strategically diversified revenue streams, said Hong Leong Investment Bank (HLIB).

The research house noted that while ASF outbreaks have historically dented the farm supplier's earnings, Yenher’s shift towards poultry premix sales has significantly reduced its reliance on the swine segment.

“During the worst ASF outbreaks in 2022 and 2023, Yenher’s core earnings declined by 5.6% and 2.4% year-on-year,” which was relatively moderate, said HLIB.

However, HLIB highlighted that Yenher, which holds exclusive distributorship for an ASF vaccine already approved in Vietnam and the Philippines, could benefit from an accelerated approval process in Malaysia due to the latest outbreak.

“Given food security concerns and inflationary pressures, there is a strong case for approval,” said HLIB.

Despite recent headwinds, HLIB maintained its ‘buy’ call on Yenher with an unchanged target price of RM1.45.

At the time of writing on Wednesday, shares of Yenher traded at 89 sen, valuing the company at RM267 million.

Edited ByIsabelle Francis
      Print
      Text Size
      Share